nodes	percent_of_prediction	percent_of_DWPC	metapath
Temsirolimus—kidney cancer—sarcoma	0.618	1	CtDrD
Temsirolimus—CYP3A7—Vincristine—sarcoma	0.0226	0.116	CbGbCtD
Temsirolimus—CYP3A7-CYP3A51P—Vincristine—sarcoma	0.0226	0.116	CbGbCtD
Temsirolimus—CYP3A4—Thiotepa—sarcoma	0.0224	0.115	CbGbCtD
Temsirolimus—ABCB1—Dactinomycin—sarcoma	0.0179	0.0919	CbGbCtD
Temsirolimus—CYP3A5—Vincristine—sarcoma	0.017	0.087	CbGbCtD
Temsirolimus—ABCB1—Mitoxantrone—sarcoma	0.016	0.0823	CbGbCtD
Temsirolimus—CYP3A5—Etoposide—sarcoma	0.0155	0.0797	CbGbCtD
Temsirolimus—ABCB1—Vincristine—sarcoma	0.011	0.0566	CbGbCtD
Temsirolimus—ABCB1—Etoposide—sarcoma	0.0101	0.0519	CbGbCtD
Temsirolimus—CYP3A4—Mitoxantrone—sarcoma	0.00962	0.0493	CbGbCtD
Temsirolimus—ABCB1—Doxorubicin—sarcoma	0.0069	0.0354	CbGbCtD
Temsirolimus—CYP3A4—Vincristine—sarcoma	0.00662	0.0339	CbGbCtD
Temsirolimus—CYP2D6—Doxorubicin—sarcoma	0.0065	0.0333	CbGbCtD
Temsirolimus—CYP3A4—Etoposide—sarcoma	0.00606	0.0311	CbGbCtD
Temsirolimus—CYP3A4—Doxorubicin—sarcoma	0.00414	0.0212	CbGbCtD
Temsirolimus—MTOR—leg—sarcoma	0.0036	0.0986	CbGeAlD
Temsirolimus—MTOR—forelimb—sarcoma	0.00357	0.0979	CbGeAlD
Temsirolimus—MTOR—hindlimb—sarcoma	0.00321	0.0881	CbGeAlD
Temsirolimus—MTOR—appendage—sarcoma	0.00276	0.0756	CbGeAlD
Temsirolimus—MTOR—mammary gland—sarcoma	0.00134	0.0368	CbGeAlD
Temsirolimus—FKBP1A—mammary gland—sarcoma	0.00121	0.0331	CbGeAlD
Temsirolimus—MTOR—myometrium—sarcoma	0.000951	0.0261	CbGeAlD
Temsirolimus—MTOR—embryo—sarcoma	0.000915	0.0251	CbGeAlD
Temsirolimus—MTOR—seminal vesicle—sarcoma	0.000859	0.0236	CbGeAlD
Temsirolimus—FKBP1A—myometrium—sarcoma	0.000856	0.0235	CbGeAlD
Temsirolimus—MTOR—hematopoietic system—sarcoma	0.000817	0.0224	CbGeAlD
Temsirolimus—MTOR—connective tissue—sarcoma	0.000786	0.0216	CbGeAlD
Temsirolimus—FKBP1A—seminal vesicle—sarcoma	0.000773	0.0212	CbGeAlD
Temsirolimus—FKBP1A—hematopoietic system—sarcoma	0.000735	0.0201	CbGeAlD
Temsirolimus—MTOR—smooth muscle tissue—sarcoma	0.000719	0.0197	CbGeAlD
Temsirolimus—MTOR—skin of body—sarcoma	0.00071	0.0195	CbGeAlD
Temsirolimus—FKBP1A—connective tissue—sarcoma	0.000707	0.0194	CbGeAlD
Temsirolimus—FKBP1A—smooth muscle tissue—sarcoma	0.000647	0.0177	CbGeAlD
Temsirolimus—FKBP1A—skin of body—sarcoma	0.000639	0.0175	CbGeAlD
Temsirolimus—MTOR—uterus—sarcoma	0.000617	0.0169	CbGeAlD
Temsirolimus—MTOR—lymphoid tissue—sarcoma	0.000575	0.0158	CbGeAlD
Temsirolimus—FKBP1A—cardiac atrium—sarcoma	0.000558	0.0153	CbGeAlD
Temsirolimus—FKBP1A—uterus—sarcoma	0.000555	0.0152	CbGeAlD
Temsirolimus—MTOR—tendon—sarcoma	0.000541	0.0148	CbGeAlD
Temsirolimus—MTOR—bone marrow—sarcoma	0.000524	0.0144	CbGeAlD
Temsirolimus—FKBP1A—lymphoid tissue—sarcoma	0.000517	0.0142	CbGeAlD
Temsirolimus—FKBP1A—tendon—sarcoma	0.000486	0.0133	CbGeAlD
Temsirolimus—FKBP1A—bone marrow—sarcoma	0.000471	0.0129	CbGeAlD
Temsirolimus—CYP3A7—liver—sarcoma	0.000471	0.0129	CbGeAlD
Temsirolimus—MTOR—testis—sarcoma	0.000448	0.0123	CbGeAlD
Temsirolimus—MTOR—liver—sarcoma	0.000423	0.0116	CbGeAlD
Temsirolimus—FKBP1A—testis—sarcoma	0.000403	0.011	CbGeAlD
Temsirolimus—CYP3A7-CYP3A51P—liver—sarcoma	0.0004	0.011	CbGeAlD
Temsirolimus—FKBP1A—liver—sarcoma	0.000381	0.0104	CbGeAlD
Temsirolimus—MTOR—lymph node—sarcoma	0.000324	0.0089	CbGeAlD
Temsirolimus—CYP3A5—hematopoietic system—sarcoma	0.00032	0.00877	CbGeAlD
Temsirolimus—FKBP1A—lymph node—sarcoma	0.000292	0.008	CbGeAlD
Temsirolimus—CYP3A4—hematopoietic system—sarcoma	0.00024	0.00658	CbGeAlD
Temsirolimus—CYP2D6—hematopoietic system—sarcoma	0.000236	0.00648	CbGeAlD
Temsirolimus—ABCB1—myometrium—sarcoma	0.000198	0.00543	CbGeAlD
Temsirolimus—ABCB1—embryo—sarcoma	0.00019	0.00522	CbGeAlD
Temsirolimus—ABCB1—seminal vesicle—sarcoma	0.000179	0.0049	CbGeAlD
Temsirolimus—ABCB1—hematopoietic system—sarcoma	0.00017	0.00466	CbGeAlD
Temsirolimus—CYP3A5—liver—sarcoma	0.000166	0.00455	CbGeAlD
Temsirolimus—CYP2D6—testis—sarcoma	0.000129	0.00355	CbGeAlD
Temsirolimus—ABCB1—uterus—sarcoma	0.000128	0.00352	CbGeAlD
Temsirolimus—CYP3A4—liver—sarcoma	0.000124	0.00341	CbGeAlD
Temsirolimus—CYP2D6—liver—sarcoma	0.000122	0.00336	CbGeAlD
Temsirolimus—ABCB1—lymphoid tissue—sarcoma	0.00012	0.00328	CbGeAlD
Temsirolimus—ABCB1—bone marrow—sarcoma	0.000109	0.00299	CbGeAlD
Temsirolimus—Cough—Etoposide—sarcoma	0.000102	0.000983	CcSEcCtD
Temsirolimus—Somnolence—Mitoxantrone—sarcoma	0.000102	0.000982	CcSEcCtD
Temsirolimus—Blood creatinine increased—Epirubicin—sarcoma	0.000102	0.000982	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Vincristine—sarcoma	0.000102	0.000979	CcSEcCtD
Temsirolimus—Fatigue—Vincristine—sarcoma	0.000102	0.000978	CcSEcCtD
Temsirolimus—Convulsion—Etoposide—sarcoma	0.000101	0.000976	CcSEcCtD
Temsirolimus—Dehydration—Epirubicin—sarcoma	0.000101	0.000975	CcSEcCtD
Temsirolimus—Hypertension—Etoposide—sarcoma	0.000101	0.000972	CcSEcCtD
Temsirolimus—Pain—Vincristine—sarcoma	0.000101	0.00097	CcSEcCtD
Temsirolimus—Constipation—Vincristine—sarcoma	0.000101	0.00097	CcSEcCtD
Temsirolimus—Gastrointestinal haemorrhage—Doxorubicin—sarcoma	0.000101	0.00097	CcSEcCtD
Temsirolimus—Dry skin—Epirubicin—sarcoma	9.98e-05	0.000961	CcSEcCtD
Temsirolimus—Decreased appetite—Mitoxantrone—sarcoma	9.98e-05	0.00096	CcSEcCtD
Temsirolimus—Chest pain—Etoposide—sarcoma	9.96e-05	0.000959	CcSEcCtD
Temsirolimus—Hypokalaemia—Epirubicin—sarcoma	9.91e-05	0.000954	CcSEcCtD
Temsirolimus—Fatigue—Mitoxantrone—sarcoma	9.9e-05	0.000953	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	9.89e-05	0.000952	CcSEcCtD
Temsirolimus—Pain—Mitoxantrone—sarcoma	9.82e-05	0.000945	CcSEcCtD
Temsirolimus—Constipation—Mitoxantrone—sarcoma	9.82e-05	0.000945	CcSEcCtD
Temsirolimus—Aspartate aminotransferase increased—Epirubicin—sarcoma	9.81e-05	0.000944	CcSEcCtD
Temsirolimus—Hypersensitivity—Thiotepa—sarcoma	9.8e-05	0.000943	CcSEcCtD
Temsirolimus—Face oedema—Doxorubicin—sarcoma	9.73e-05	0.000936	CcSEcCtD
Temsirolimus—Hypersensitivity—Dactinomycin—sarcoma	9.72e-05	0.000935	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Vincristine—sarcoma	9.64e-05	0.000928	CcSEcCtD
Temsirolimus—Gastritis—Epirubicin—sarcoma	9.64e-05	0.000928	CcSEcCtD
Temsirolimus—Alanine aminotransferase increased—Epirubicin—sarcoma	9.61e-05	0.000924	CcSEcCtD
Temsirolimus—Anaphylactic shock—Etoposide—sarcoma	9.55e-05	0.000919	CcSEcCtD
Temsirolimus—Asthenia—Thiotepa—sarcoma	9.54e-05	0.000918	CcSEcCtD
Temsirolimus—Infection—Etoposide—sarcoma	9.49e-05	0.000913	CcSEcCtD
Temsirolimus—Abdominal distension—Epirubicin—sarcoma	9.48e-05	0.000912	CcSEcCtD
Temsirolimus—Asthenia—Dactinomycin—sarcoma	9.47e-05	0.000911	CcSEcCtD
Temsirolimus—Blood creatinine increased—Doxorubicin—sarcoma	9.44e-05	0.000909	CcSEcCtD
Temsirolimus—Influenza—Epirubicin—sarcoma	9.41e-05	0.000906	CcSEcCtD
Temsirolimus—Dysphagia—Epirubicin—sarcoma	9.41e-05	0.000906	CcSEcCtD
Temsirolimus—Pruritus—Thiotepa—sarcoma	9.41e-05	0.000905	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Mitoxantrone—sarcoma	9.39e-05	0.000903	CcSEcCtD
Temsirolimus—Dehydration—Doxorubicin—sarcoma	9.37e-05	0.000902	CcSEcCtD
Temsirolimus—Thrombocytopenia—Etoposide—sarcoma	9.35e-05	0.0009	CcSEcCtD
Temsirolimus—Body temperature increased—Vincristine—sarcoma	9.32e-05	0.000897	CcSEcCtD
Temsirolimus—Abdominal pain—Vincristine—sarcoma	9.32e-05	0.000897	CcSEcCtD
Temsirolimus—ABCB1—testis—sarcoma	9.31e-05	0.00255	CbGeAlD
Temsirolimus—Skin disorder—Etoposide—sarcoma	9.28e-05	0.000893	CcSEcCtD
Temsirolimus—Dry skin—Doxorubicin—sarcoma	9.24e-05	0.000889	CcSEcCtD
Temsirolimus—Hypokalaemia—Doxorubicin—sarcoma	9.17e-05	0.000883	CcSEcCtD
Temsirolimus—Anorexia—Etoposide—sarcoma	9.1e-05	0.000876	CcSEcCtD
Temsirolimus—Diarrhoea—Thiotepa—sarcoma	9.1e-05	0.000875	CcSEcCtD
Temsirolimus—Abdominal pain—Mitoxantrone—sarcoma	9.08e-05	0.000873	CcSEcCtD
Temsirolimus—Body temperature increased—Mitoxantrone—sarcoma	9.08e-05	0.000873	CcSEcCtD
Temsirolimus—Aspartate aminotransferase increased—Doxorubicin—sarcoma	9.08e-05	0.000873	CcSEcCtD
Temsirolimus—Bronchitis—Epirubicin—sarcoma	9.05e-05	0.000871	CcSEcCtD
Temsirolimus—Diarrhoea—Dactinomycin—sarcoma	9.03e-05	0.000869	CcSEcCtD
Temsirolimus—Gastritis—Doxorubicin—sarcoma	8.92e-05	0.000858	CcSEcCtD
Temsirolimus—Alanine aminotransferase increased—Doxorubicin—sarcoma	8.89e-05	0.000855	CcSEcCtD
Temsirolimus—ABCB1—liver—sarcoma	8.8e-05	0.00241	CbGeAlD
Temsirolimus—Neutropenia—Epirubicin—sarcoma	8.8e-05	0.000847	CcSEcCtD
Temsirolimus—Dysuria—Epirubicin—sarcoma	8.8e-05	0.000847	CcSEcCtD
Temsirolimus—Dizziness—Thiotepa—sarcoma	8.79e-05	0.000846	CcSEcCtD
Temsirolimus—Abdominal distension—Doxorubicin—sarcoma	8.77e-05	0.000844	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Epirubicin—sarcoma	8.75e-05	0.000842	CcSEcCtD
Temsirolimus—Dysphagia—Doxorubicin—sarcoma	8.71e-05	0.000838	CcSEcCtD
Temsirolimus—Influenza—Doxorubicin—sarcoma	8.71e-05	0.000838	CcSEcCtD
Temsirolimus—Pollakiuria—Epirubicin—sarcoma	8.7e-05	0.000837	CcSEcCtD
Temsirolimus—Hypersensitivity—Vincristine—sarcoma	8.69e-05	0.000836	CcSEcCtD
Temsirolimus—Weight decreased—Epirubicin—sarcoma	8.52e-05	0.00082	CcSEcCtD
Temsirolimus—Dyspnoea—Etoposide—sarcoma	8.52e-05	0.000819	CcSEcCtD
Temsirolimus—Hyperglycaemia—Epirubicin—sarcoma	8.49e-05	0.000817	CcSEcCtD
Temsirolimus—Somnolence—Etoposide—sarcoma	8.49e-05	0.000817	CcSEcCtD
Temsirolimus—Hypersensitivity—Mitoxantrone—sarcoma	8.46e-05	0.000814	CcSEcCtD
Temsirolimus—Asthenia—Vincristine—sarcoma	8.46e-05	0.000814	CcSEcCtD
Temsirolimus—Vomiting—Thiotepa—sarcoma	8.45e-05	0.000813	CcSEcCtD
Temsirolimus—Pneumonia—Epirubicin—sarcoma	8.44e-05	0.000812	CcSEcCtD
Temsirolimus—Infestation NOS—Epirubicin—sarcoma	8.39e-05	0.000808	CcSEcCtD
Temsirolimus—Infestation—Epirubicin—sarcoma	8.39e-05	0.000808	CcSEcCtD
Temsirolimus—Vomiting—Dactinomycin—sarcoma	8.39e-05	0.000807	CcSEcCtD
Temsirolimus—Rash—Thiotepa—sarcoma	8.38e-05	0.000807	CcSEcCtD
Temsirolimus—Bronchitis—Doxorubicin—sarcoma	8.38e-05	0.000806	CcSEcCtD
Temsirolimus—Dermatitis—Thiotepa—sarcoma	8.38e-05	0.000806	CcSEcCtD
Temsirolimus—Headache—Thiotepa—sarcoma	8.33e-05	0.000801	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Epirubicin—sarcoma	8.32e-05	0.000801	CcSEcCtD
Temsirolimus—Rash—Dactinomycin—sarcoma	8.32e-05	0.000801	CcSEcCtD
Temsirolimus—Decreased appetite—Etoposide—sarcoma	8.3e-05	0.000799	CcSEcCtD
Temsirolimus—Renal failure—Epirubicin—sarcoma	8.25e-05	0.000794	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Etoposide—sarcoma	8.25e-05	0.000793	CcSEcCtD
Temsirolimus—Asthenia—Mitoxantrone—sarcoma	8.24e-05	0.000793	CcSEcCtD
Temsirolimus—Fatigue—Etoposide—sarcoma	8.23e-05	0.000792	CcSEcCtD
Temsirolimus—Stomatitis—Epirubicin—sarcoma	8.18e-05	0.000787	CcSEcCtD
Temsirolimus—Pain—Etoposide—sarcoma	8.17e-05	0.000786	CcSEcCtD
Temsirolimus—Constipation—Etoposide—sarcoma	8.17e-05	0.000786	CcSEcCtD
Temsirolimus—Conjunctivitis—Epirubicin—sarcoma	8.16e-05	0.000785	CcSEcCtD
Temsirolimus—Urinary tract infection—Epirubicin—sarcoma	8.16e-05	0.000785	CcSEcCtD
Temsirolimus—Dysuria—Doxorubicin—sarcoma	8.15e-05	0.000784	CcSEcCtD
Temsirolimus—Neutropenia—Doxorubicin—sarcoma	8.15e-05	0.000784	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Doxorubicin—sarcoma	8.1e-05	0.000779	CcSEcCtD
Temsirolimus—Diarrhoea—Vincristine—sarcoma	8.07e-05	0.000776	CcSEcCtD
Temsirolimus—Pollakiuria—Doxorubicin—sarcoma	8.05e-05	0.000774	CcSEcCtD
Temsirolimus—Haematuria—Epirubicin—sarcoma	8e-05	0.00077	CcSEcCtD
Temsirolimus—Epistaxis—Epirubicin—sarcoma	7.92e-05	0.000762	CcSEcCtD
Temsirolimus—Nausea—Thiotepa—sarcoma	7.9e-05	0.00076	CcSEcCtD
Temsirolimus—Weight decreased—Doxorubicin—sarcoma	7.88e-05	0.000758	CcSEcCtD
Temsirolimus—Sinusitis—Epirubicin—sarcoma	7.88e-05	0.000758	CcSEcCtD
Temsirolimus—Hyperglycaemia—Doxorubicin—sarcoma	7.86e-05	0.000756	CcSEcCtD
Temsirolimus—Diarrhoea—Mitoxantrone—sarcoma	7.86e-05	0.000756	CcSEcCtD
Temsirolimus—Nausea—Dactinomycin—sarcoma	7.84e-05	0.000754	CcSEcCtD
Temsirolimus—Pneumonia—Doxorubicin—sarcoma	7.81e-05	0.000752	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Etoposide—sarcoma	7.81e-05	0.000751	CcSEcCtD
Temsirolimus—Dizziness—Vincristine—sarcoma	7.8e-05	0.00075	CcSEcCtD
Temsirolimus—Infestation NOS—Doxorubicin—sarcoma	7.77e-05	0.000747	CcSEcCtD
Temsirolimus—Infestation—Doxorubicin—sarcoma	7.77e-05	0.000747	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Doxorubicin—sarcoma	7.7e-05	0.000741	CcSEcCtD
Temsirolimus—Renal failure—Doxorubicin—sarcoma	7.64e-05	0.000735	CcSEcCtD
Temsirolimus—Stomatitis—Doxorubicin—sarcoma	7.57e-05	0.000728	CcSEcCtD
Temsirolimus—Rhinitis—Epirubicin—sarcoma	7.55e-05	0.000727	CcSEcCtD
Temsirolimus—Abdominal pain—Etoposide—sarcoma	7.55e-05	0.000726	CcSEcCtD
Temsirolimus—Body temperature increased—Etoposide—sarcoma	7.55e-05	0.000726	CcSEcCtD
Temsirolimus—Conjunctivitis—Doxorubicin—sarcoma	7.55e-05	0.000726	CcSEcCtD
Temsirolimus—Urinary tract infection—Doxorubicin—sarcoma	7.55e-05	0.000726	CcSEcCtD
Temsirolimus—Vomiting—Vincristine—sarcoma	7.5e-05	0.000721	CcSEcCtD
Temsirolimus—Pharyngitis—Epirubicin—sarcoma	7.48e-05	0.00072	CcSEcCtD
Temsirolimus—Urinary tract disorder—Epirubicin—sarcoma	7.44e-05	0.000716	CcSEcCtD
Temsirolimus—Rash—Vincristine—sarcoma	7.43e-05	0.000715	CcSEcCtD
Temsirolimus—Dermatitis—Vincristine—sarcoma	7.43e-05	0.000715	CcSEcCtD
Temsirolimus—Oedema peripheral—Epirubicin—sarcoma	7.42e-05	0.000714	CcSEcCtD
Temsirolimus—Haematuria—Doxorubicin—sarcoma	7.41e-05	0.000713	CcSEcCtD
Temsirolimus—Connective tissue disorder—Epirubicin—sarcoma	7.41e-05	0.000713	CcSEcCtD
Temsirolimus—Urethral disorder—Epirubicin—sarcoma	7.39e-05	0.000711	CcSEcCtD
Temsirolimus—Headache—Vincristine—sarcoma	7.39e-05	0.000711	CcSEcCtD
Temsirolimus—Epistaxis—Doxorubicin—sarcoma	7.33e-05	0.000705	CcSEcCtD
Temsirolimus—Vomiting—Mitoxantrone—sarcoma	7.3e-05	0.000702	CcSEcCtD
Temsirolimus—Sinusitis—Doxorubicin—sarcoma	7.29e-05	0.000701	CcSEcCtD
Temsirolimus—Rash—Mitoxantrone—sarcoma	7.24e-05	0.000697	CcSEcCtD
Temsirolimus—Dermatitis—Mitoxantrone—sarcoma	7.23e-05	0.000696	CcSEcCtD
Temsirolimus—Headache—Mitoxantrone—sarcoma	7.19e-05	0.000692	CcSEcCtD
Temsirolimus—Erythema multiforme—Epirubicin—sarcoma	7.13e-05	0.000686	CcSEcCtD
Temsirolimus—Eye disorder—Epirubicin—sarcoma	7.04e-05	0.000678	CcSEcCtD
Temsirolimus—Hypersensitivity—Etoposide—sarcoma	7.04e-05	0.000677	CcSEcCtD
Temsirolimus—Nausea—Vincristine—sarcoma	7e-05	0.000674	CcSEcCtD
Temsirolimus—Cardiac disorder—Epirubicin—sarcoma	6.99e-05	0.000673	CcSEcCtD
Temsirolimus—Rhinitis—Doxorubicin—sarcoma	6.99e-05	0.000673	CcSEcCtD
Temsirolimus—Pharyngitis—Doxorubicin—sarcoma	6.92e-05	0.000666	CcSEcCtD
Temsirolimus—Urinary tract disorder—Doxorubicin—sarcoma	6.89e-05	0.000663	CcSEcCtD
Temsirolimus—Oedema peripheral—Doxorubicin—sarcoma	6.87e-05	0.000661	CcSEcCtD
Temsirolimus—Asthenia—Etoposide—sarcoma	6.85e-05	0.000659	CcSEcCtD
Temsirolimus—Connective tissue disorder—Doxorubicin—sarcoma	6.85e-05	0.000659	CcSEcCtD
Temsirolimus—Angiopathy—Epirubicin—sarcoma	6.84e-05	0.000658	CcSEcCtD
Temsirolimus—Urethral disorder—Doxorubicin—sarcoma	6.84e-05	0.000658	CcSEcCtD
Temsirolimus—Nausea—Mitoxantrone—sarcoma	6.82e-05	0.000656	CcSEcCtD
Temsirolimus—Immune system disorder—Epirubicin—sarcoma	6.81e-05	0.000655	CcSEcCtD
Temsirolimus—Mediastinal disorder—Epirubicin—sarcoma	6.79e-05	0.000653	CcSEcCtD
Temsirolimus—Chills—Epirubicin—sarcoma	6.76e-05	0.000651	CcSEcCtD
Temsirolimus—Pruritus—Etoposide—sarcoma	6.76e-05	0.00065	CcSEcCtD
Temsirolimus—ABCB1—lymph node—sarcoma	6.75e-05	0.00185	CbGeAlD
Temsirolimus—Mental disorder—Epirubicin—sarcoma	6.6e-05	0.000635	CcSEcCtD
Temsirolimus—Erythema multiforme—Doxorubicin—sarcoma	6.59e-05	0.000634	CcSEcCtD
Temsirolimus—Erythema—Epirubicin—sarcoma	6.56e-05	0.000631	CcSEcCtD
Temsirolimus—Malnutrition—Epirubicin—sarcoma	6.56e-05	0.000631	CcSEcCtD
Temsirolimus—Diarrhoea—Etoposide—sarcoma	6.53e-05	0.000629	CcSEcCtD
Temsirolimus—Eye disorder—Doxorubicin—sarcoma	6.52e-05	0.000627	CcSEcCtD
Temsirolimus—Cardiac disorder—Doxorubicin—sarcoma	6.47e-05	0.000623	CcSEcCtD
Temsirolimus—Dysgeusia—Epirubicin—sarcoma	6.42e-05	0.000618	CcSEcCtD
Temsirolimus—Back pain—Epirubicin—sarcoma	6.35e-05	0.000611	CcSEcCtD
Temsirolimus—Angiopathy—Doxorubicin—sarcoma	6.33e-05	0.000609	CcSEcCtD
Temsirolimus—Dizziness—Etoposide—sarcoma	6.32e-05	0.000608	CcSEcCtD
Temsirolimus—Immune system disorder—Doxorubicin—sarcoma	6.3e-05	0.000606	CcSEcCtD
Temsirolimus—Mediastinal disorder—Doxorubicin—sarcoma	6.28e-05	0.000605	CcSEcCtD
Temsirolimus—Chills—Doxorubicin—sarcoma	6.26e-05	0.000602	CcSEcCtD
Temsirolimus—Mental disorder—Doxorubicin—sarcoma	6.11e-05	0.000588	CcSEcCtD
Temsirolimus—Vomiting—Etoposide—sarcoma	6.07e-05	0.000584	CcSEcCtD
Temsirolimus—Erythema—Doxorubicin—sarcoma	6.07e-05	0.000584	CcSEcCtD
Temsirolimus—Malnutrition—Doxorubicin—sarcoma	6.07e-05	0.000584	CcSEcCtD
Temsirolimus—Anaemia—Epirubicin—sarcoma	6.06e-05	0.000583	CcSEcCtD
Temsirolimus—Rash—Etoposide—sarcoma	6.02e-05	0.000579	CcSEcCtD
Temsirolimus—Dermatitis—Etoposide—sarcoma	6.02e-05	0.000579	CcSEcCtD
Temsirolimus—Headache—Etoposide—sarcoma	5.98e-05	0.000576	CcSEcCtD
Temsirolimus—Dysgeusia—Doxorubicin—sarcoma	5.94e-05	0.000572	CcSEcCtD
Temsirolimus—Leukopenia—Epirubicin—sarcoma	5.87e-05	0.000565	CcSEcCtD
Temsirolimus—Back pain—Doxorubicin—sarcoma	5.87e-05	0.000565	CcSEcCtD
Temsirolimus—Cough—Epirubicin—sarcoma	5.72e-05	0.000551	CcSEcCtD
Temsirolimus—Convulsion—Epirubicin—sarcoma	5.68e-05	0.000547	CcSEcCtD
Temsirolimus—Nausea—Etoposide—sarcoma	5.67e-05	0.000546	CcSEcCtD
Temsirolimus—Hypertension—Epirubicin—sarcoma	5.66e-05	0.000545	CcSEcCtD
Temsirolimus—Anaemia—Doxorubicin—sarcoma	5.61e-05	0.00054	CcSEcCtD
Temsirolimus—Arthralgia—Epirubicin—sarcoma	5.58e-05	0.000537	CcSEcCtD
Temsirolimus—Chest pain—Epirubicin—sarcoma	5.58e-05	0.000537	CcSEcCtD
Temsirolimus—Myalgia—Epirubicin—sarcoma	5.58e-05	0.000537	CcSEcCtD
Temsirolimus—Anxiety—Epirubicin—sarcoma	5.57e-05	0.000535	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	5.55e-05	0.000534	CcSEcCtD
Temsirolimus—Leukopenia—Doxorubicin—sarcoma	5.43e-05	0.000523	CcSEcCtD
Temsirolimus—Oedema—Epirubicin—sarcoma	5.35e-05	0.000515	CcSEcCtD
Temsirolimus—Anaphylactic shock—Epirubicin—sarcoma	5.35e-05	0.000515	CcSEcCtD
Temsirolimus—Infection—Epirubicin—sarcoma	5.32e-05	0.000512	CcSEcCtD
Temsirolimus—Cough—Doxorubicin—sarcoma	5.3e-05	0.00051	CcSEcCtD
Temsirolimus—Convulsion—Doxorubicin—sarcoma	5.26e-05	0.000506	CcSEcCtD
Temsirolimus—Nervous system disorder—Epirubicin—sarcoma	5.25e-05	0.000505	CcSEcCtD
Temsirolimus—Thrombocytopenia—Epirubicin—sarcoma	5.24e-05	0.000504	CcSEcCtD
Temsirolimus—Hypertension—Doxorubicin—sarcoma	5.24e-05	0.000504	CcSEcCtD
Temsirolimus—Skin disorder—Epirubicin—sarcoma	5.2e-05	0.0005	CcSEcCtD
Temsirolimus—Chest pain—Doxorubicin—sarcoma	5.17e-05	0.000497	CcSEcCtD
Temsirolimus—Arthralgia—Doxorubicin—sarcoma	5.17e-05	0.000497	CcSEcCtD
Temsirolimus—Myalgia—Doxorubicin—sarcoma	5.17e-05	0.000497	CcSEcCtD
Temsirolimus—Anxiety—Doxorubicin—sarcoma	5.15e-05	0.000495	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	5.13e-05	0.000494	CcSEcCtD
Temsirolimus—Anorexia—Epirubicin—sarcoma	5.1e-05	0.000491	CcSEcCtD
Temsirolimus—Oedema—Doxorubicin—sarcoma	4.95e-05	0.000477	CcSEcCtD
Temsirolimus—Anaphylactic shock—Doxorubicin—sarcoma	4.95e-05	0.000477	CcSEcCtD
Temsirolimus—Infection—Doxorubicin—sarcoma	4.92e-05	0.000474	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Epirubicin—sarcoma	4.88e-05	0.000469	CcSEcCtD
Temsirolimus—Nervous system disorder—Doxorubicin—sarcoma	4.86e-05	0.000467	CcSEcCtD
Temsirolimus—Thrombocytopenia—Doxorubicin—sarcoma	4.85e-05	0.000467	CcSEcCtD
Temsirolimus—Insomnia—Epirubicin—sarcoma	4.84e-05	0.000466	CcSEcCtD
Temsirolimus—Skin disorder—Doxorubicin—sarcoma	4.81e-05	0.000463	CcSEcCtD
Temsirolimus—Dyspnoea—Epirubicin—sarcoma	4.77e-05	0.000459	CcSEcCtD
Temsirolimus—Somnolence—Epirubicin—sarcoma	4.76e-05	0.000458	CcSEcCtD
Temsirolimus—Anorexia—Doxorubicin—sarcoma	4.72e-05	0.000454	CcSEcCtD
Temsirolimus—Decreased appetite—Epirubicin—sarcoma	4.65e-05	0.000448	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Epirubicin—sarcoma	4.62e-05	0.000445	CcSEcCtD
Temsirolimus—Fatigue—Epirubicin—sarcoma	4.62e-05	0.000444	CcSEcCtD
Temsirolimus—Pain—Epirubicin—sarcoma	4.58e-05	0.000441	CcSEcCtD
Temsirolimus—Constipation—Epirubicin—sarcoma	4.58e-05	0.000441	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Doxorubicin—sarcoma	4.51e-05	0.000434	CcSEcCtD
Temsirolimus—Insomnia—Doxorubicin—sarcoma	4.48e-05	0.000431	CcSEcCtD
Temsirolimus—Dyspnoea—Doxorubicin—sarcoma	4.42e-05	0.000425	CcSEcCtD
Temsirolimus—MTOR—Signaling by FGFR—SRC—sarcoma	4.41e-05	0.000946	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—SRC—sarcoma	4.41e-05	0.000946	CbGpPWpGaD
Temsirolimus—Somnolence—Doxorubicin—sarcoma	4.4e-05	0.000424	CcSEcCtD
Temsirolimus—MTOR—ErbB1 downstream signaling—HRAS—sarcoma	4.4e-05	0.000942	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—sarcoma	4.4e-05	0.000942	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—SRC—sarcoma	4.39e-05	0.000942	CbGpPWpGaD
Temsirolimus—Gastrointestinal pain—Epirubicin—sarcoma	4.38e-05	0.000421	CcSEcCtD
Temsirolimus—ABCB1—HIF-1-alpha transcription factor network—JUN—sarcoma	4.35e-05	0.000932	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—CREB1—sarcoma	4.34e-05	0.000931	CbGpPWpGaD
Temsirolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—sarcoma	4.33e-05	0.000928	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—EGFR—sarcoma	4.32e-05	0.000927	CbGpPWpGaD
Temsirolimus—Decreased appetite—Doxorubicin—sarcoma	4.31e-05	0.000414	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Doxorubicin—sarcoma	4.28e-05	0.000411	CcSEcCtD
Temsirolimus—Fatigue—Doxorubicin—sarcoma	4.27e-05	0.000411	CcSEcCtD
Temsirolimus—MTOR—Downstream signal transduction—NRAS—sarcoma	4.27e-05	0.000915	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—NRAS—sarcoma	4.25e-05	0.00091	CbGpPWpGaD
Temsirolimus—Constipation—Doxorubicin—sarcoma	4.24e-05	0.000408	CcSEcCtD
Temsirolimus—Pain—Doxorubicin—sarcoma	4.24e-05	0.000408	CcSEcCtD
Temsirolimus—Abdominal pain—Epirubicin—sarcoma	4.23e-05	0.000407	CcSEcCtD
Temsirolimus—Body temperature increased—Epirubicin—sarcoma	4.23e-05	0.000407	CcSEcCtD
Temsirolimus—MTOR—Signaling by ERBB2—NRAS—sarcoma	4.23e-05	0.000906	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—NRAS—sarcoma	4.21e-05	0.000902	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—MYC—sarcoma	4.19e-05	0.000897	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—sarcoma	4.15e-05	0.000889	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—EGFR—sarcoma	4.14e-05	0.000887	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—SRC—sarcoma	4.11e-05	0.000882	CbGpPWpGaD
Temsirolimus—CYP3A4—Tryptophan metabolism—MDM2—sarcoma	4.11e-05	0.000881	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—VEGFC—sarcoma	4.1e-05	0.000879	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—sarcoma	4.09e-05	0.000877	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by VEGF—HRAS—sarcoma	4.09e-05	0.000876	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—KRAS—sarcoma	4.09e-05	0.000876	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—SRC—sarcoma	4.08e-05	0.000874	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—EGFR—sarcoma	4.07e-05	0.000873	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by Insulin receptor—HRAS—sarcoma	4.06e-05	0.00087	CbGpPWpGaD
Temsirolimus—Gastrointestinal pain—Doxorubicin—sarcoma	4.05e-05	0.00039	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—SRC—sarcoma	4.04e-05	0.000866	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—SRC—sarcoma	4.02e-05	0.000862	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CD34—sarcoma	3.96e-05	0.000849	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—NRAS—sarcoma	3.96e-05	0.000848	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—sarcoma	3.96e-05	0.000848	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—NRAS—sarcoma	3.96e-05	0.000848	CbGpPWpGaD
Temsirolimus—Hypersensitivity—Epirubicin—sarcoma	3.94e-05	0.00038	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR—NRAS—sarcoma	3.92e-05	0.000841	CbGpPWpGaD
Temsirolimus—Abdominal pain—Doxorubicin—sarcoma	3.92e-05	0.000377	CcSEcCtD
Temsirolimus—Body temperature increased—Doxorubicin—sarcoma	3.92e-05	0.000377	CcSEcCtD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—KRAS—sarcoma	3.91e-05	0.000838	CbGpPWpGaD
Temsirolimus—MTOR—Disease—TLE1—sarcoma	3.9e-05	0.000837	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—EGFR—sarcoma	3.89e-05	0.000834	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—NRAS—sarcoma	3.89e-05	0.000833	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—sarcoma	3.87e-05	0.000829	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—EGFR—sarcoma	3.87e-05	0.000829	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—NRAS—sarcoma	3.87e-05	0.000829	CbGpPWpGaD
Temsirolimus—ABCB1—Allograft Rejection—IL2—sarcoma	3.87e-05	0.000829	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—KRAS—sarcoma	3.87e-05	0.000829	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—EGFR—sarcoma	3.85e-05	0.000825	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—KRAS—sarcoma	3.85e-05	0.000825	CbGpPWpGaD
Temsirolimus—Asthenia—Epirubicin—sarcoma	3.84e-05	0.00037	CcSEcCtD
Temsirolimus—MTOR—DAP12 signaling—EGFR—sarcoma	3.83e-05	0.000821	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—MDM2—sarcoma	3.83e-05	0.000821	CbGpPWpGaD
Temsirolimus—ABCB1—HIF-1-alpha transcription factor network—VEGFA—sarcoma	3.8e-05	0.000814	CbGpPWpGaD
Temsirolimus—Pruritus—Epirubicin—sarcoma	3.79e-05	0.000364	CcSEcCtD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—sarcoma	3.78e-05	0.00081	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—KRAS—sarcoma	3.67e-05	0.000787	CbGpPWpGaD
Temsirolimus—Diarrhoea—Epirubicin—sarcoma	3.66e-05	0.000352	CcSEcCtD
Temsirolimus—MTOR—B Cell Activation—NRAS—sarcoma	3.66e-05	0.000785	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—sarcoma	3.66e-05	0.000784	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—KRAS—sarcoma	3.66e-05	0.000784	CbGpPWpGaD
Temsirolimus—Hypersensitivity—Doxorubicin—sarcoma	3.65e-05	0.000351	CcSEcCtD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—SRC—sarcoma	3.64e-05	0.000781	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—KRAS—sarcoma	3.64e-05	0.00078	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—KRAS—sarcoma	3.62e-05	0.000776	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—sarcoma	3.61e-05	0.000773	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—EGFR—sarcoma	3.61e-05	0.000773	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—EGFR—sarcoma	3.61e-05	0.000773	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—MDM2—sarcoma	3.59e-05	0.00077	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—EGFR—sarcoma	3.57e-05	0.000766	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—sarcoma	3.57e-05	0.000765	CbGpPWpGaD
Temsirolimus—Asthenia—Doxorubicin—sarcoma	3.55e-05	0.000342	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—EGFR—sarcoma	3.54e-05	0.000759	CbGpPWpGaD
Temsirolimus—Dizziness—Epirubicin—sarcoma	3.54e-05	0.000341	CcSEcCtD
Temsirolimus—MTOR—Signaling by PDGF—EGFR—sarcoma	3.53e-05	0.000756	CbGpPWpGaD
Temsirolimus—MTOR—Disease—NPM1—sarcoma	3.52e-05	0.000755	CbGpPWpGaD
Temsirolimus—Pruritus—Doxorubicin—sarcoma	3.5e-05	0.000337	CcSEcCtD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—sarcoma	3.5e-05	0.000751	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	3.5e-05	0.00075	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—HRAS—sarcoma	3.47e-05	0.000744	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—sarcoma	3.44e-05	0.000737	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—FOXO1—sarcoma	3.42e-05	0.000732	CbGpPWpGaD
Temsirolimus—MTOR—BDNF signaling pathway—HRAS—sarcoma	3.41e-05	0.000732	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—PDGFRB—sarcoma	3.41e-05	0.000731	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—sarcoma	3.41e-05	0.00073	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—KRAS—sarcoma	3.41e-05	0.00073	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—KRAS—sarcoma	3.41e-05	0.00073	CbGpPWpGaD
Temsirolimus—Vomiting—Epirubicin—sarcoma	3.4e-05	0.000328	CcSEcCtD
Temsirolimus—Diarrhoea—Doxorubicin—sarcoma	3.39e-05	0.000326	CcSEcCtD
Temsirolimus—Rash—Epirubicin—sarcoma	3.38e-05	0.000325	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR—KRAS—sarcoma	3.38e-05	0.000723	CbGpPWpGaD
Temsirolimus—Dermatitis—Epirubicin—sarcoma	3.37e-05	0.000324	CcSEcCtD
Temsirolimus—MTOR—Innate Immune System—PDGFRA—sarcoma	3.36e-05	0.000719	CbGpPWpGaD
Temsirolimus—Headache—Epirubicin—sarcoma	3.35e-05	0.000323	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—KRAS—sarcoma	3.35e-05	0.000717	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—EGFR—sarcoma	3.34e-05	0.000715	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—KRAS—sarcoma	3.33e-05	0.000714	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—JUN—sarcoma	3.33e-05	0.000714	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—HRAS—sarcoma	3.32e-05	0.000712	CbGpPWpGaD
Temsirolimus—ABCB1—Allograft Rejection—VEGFA—sarcoma	3.29e-05	0.000705	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—FOXO1—sarcoma	3.28e-05	0.000703	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—FLT1—sarcoma	3.28e-05	0.000703	CbGpPWpGaD
Temsirolimus—Dizziness—Doxorubicin—sarcoma	3.28e-05	0.000315	CcSEcCtD
Temsirolimus—MTOR—Adaptive Immune System—PDGFRB—sarcoma	3.27e-05	0.000702	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—HRAS—sarcoma	3.27e-05	0.000701	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—FOXO1—sarcoma	3.27e-05	0.0007	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PDGFRB—sarcoma	3.26e-05	0.000699	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PLCG1—sarcoma	3.22e-05	0.000691	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—PDGFRA—sarcoma	3.22e-05	0.000691	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PDGFRA—sarcoma	3.21e-05	0.000688	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—sarcoma	3.19e-05	0.000684	CbGpPWpGaD
Temsirolimus—Nausea—Epirubicin—sarcoma	3.18e-05	0.000306	CcSEcCtD
Temsirolimus—MTOR—B Cell Activation—KRAS—sarcoma	3.15e-05	0.000676	CbGpPWpGaD
Temsirolimus—Vomiting—Doxorubicin—sarcoma	3.15e-05	0.000303	CcSEcCtD
Temsirolimus—MTOR—Insulin Signaling—HRAS—sarcoma	3.14e-05	0.000673	CbGpPWpGaD
Temsirolimus—Rash—Doxorubicin—sarcoma	3.12e-05	0.000301	CcSEcCtD
Temsirolimus—MTOR—Downstream signal transduction—HRAS—sarcoma	3.12e-05	0.000669	CbGpPWpGaD
Temsirolimus—Dermatitis—Doxorubicin—sarcoma	3.12e-05	0.0003	CcSEcCtD
Temsirolimus—MTOR—Signaling by FGFR—HRAS—sarcoma	3.11e-05	0.000666	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—sarcoma	3.11e-05	0.000666	CbGpPWpGaD
Temsirolimus—Headache—Doxorubicin—sarcoma	3.1e-05	0.000299	CcSEcCtD
Temsirolimus—FKBP1A—Signaling Pathways—CXCR4—sarcoma	3.1e-05	0.000664	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—HRAS—sarcoma	3.09e-05	0.000663	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—HRAS—sarcoma	3.08e-05	0.00066	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—ATF1—sarcoma	3.06e-05	0.000656	CbGpPWpGaD
Temsirolimus—MTOR—Disease—ENO2—sarcoma	3.05e-05	0.000654	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—sarcoma	3.03e-05	0.00065	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—sarcoma	3.02e-05	0.000647	CbGpPWpGaD
Temsirolimus—Nausea—Doxorubicin—sarcoma	2.94e-05	0.000283	CcSEcCtD
Temsirolimus—MTOR—Cellular responses to stress—VEGFA—sarcoma	2.91e-05	0.000624	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—HRAS—sarcoma	2.89e-05	0.00062	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—HRAS—sarcoma	2.89e-05	0.00062	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—sarcoma	2.89e-05	0.00062	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—HRAS—sarcoma	2.87e-05	0.000615	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PTPRC—sarcoma	2.87e-05	0.000614	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—HRAS—sarcoma	2.84e-05	0.00061	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—HRAS—sarcoma	2.83e-05	0.000607	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PLCG1—sarcoma	2.8e-05	0.000601	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—SRC—sarcoma	2.8e-05	0.000601	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TLE1—sarcoma	2.73e-05	0.000586	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—NRAS—sarcoma	2.7e-05	0.000578	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—HRAS—sarcoma	2.68e-05	0.000574	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—ATF1—sarcoma	2.66e-05	0.000571	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—KIT—sarcoma	2.6e-05	0.000558	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PLCG1—sarcoma	2.59e-05	0.000555	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	2.58e-05	0.000554	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—sarcoma	2.56e-05	0.00055	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—KIT—sarcoma	2.5e-05	0.000536	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—KIT—sarcoma	2.49e-05	0.000533	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CXCR4—sarcoma	2.49e-05	0.000533	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—CREB1—sarcoma	2.48e-05	0.000531	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—EGFR—sarcoma	2.46e-05	0.000526	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—IGF1R—sarcoma	2.4e-05	0.000515	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—CREB1—sarcoma	2.38e-05	0.00051	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—CREB1—sarcoma	2.37e-05	0.000508	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—KRAS—sarcoma	2.32e-05	0.000497	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—VEGFC—sarcoma	2.31e-05	0.000494	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—FOXO1—sarcoma	2.29e-05	0.00049	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PDGFRB—sarcoma	2.28e-05	0.000489	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PDGFRA—sarcoma	2.25e-05	0.000482	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—TP53—sarcoma	2.2e-05	0.000471	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	2.14e-05	0.000458	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—MDM2—sarcoma	2.05e-05	0.000439	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—ENO2—sarcoma	2.02e-05	0.000432	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—HBA1—sarcoma	2e-05	0.00043	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—FOXO1—sarcoma	1.99e-05	0.000426	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PDGFRB—sarcoma	1.99e-05	0.000426	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—HRAS—sarcoma	1.97e-05	0.000423	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—MDM2—sarcoma	1.97e-05	0.000422	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—MDM2—sarcoma	1.96e-05	0.00042	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PDGFRA—sarcoma	1.95e-05	0.000419	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—KDR—sarcoma	1.89e-05	0.000405	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	1.86e-05	0.000399	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	1.86e-05	0.000398	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—FLT1—sarcoma	1.84e-05	0.000395	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	1.84e-05	0.000395	CbGpPWpGaD
Temsirolimus—MTOR—Disease—FOXO1—sarcoma	1.84e-05	0.000394	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PDGFRB—sarcoma	1.83e-05	0.000393	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PLCG1—sarcoma	1.81e-05	0.000389	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PDGFRA—sarcoma	1.8e-05	0.000387	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—JUN—sarcoma	1.78e-05	0.000382	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—CTNNB1—sarcoma	1.77e-05	0.000379	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—KIT—sarcoma	1.74e-05	0.000374	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CXCR4—sarcoma	1.74e-05	0.000373	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—ATF1—sarcoma	1.72e-05	0.000369	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PLCG1—sarcoma	1.71e-05	0.000367	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—CTNNB1—sarcoma	1.69e-05	0.000362	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	1.67e-05	0.000357	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CREB1—sarcoma	1.66e-05	0.000356	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	1.62e-05	0.000348	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—SRC—sarcoma	1.6e-05	0.000343	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—NRAS—sarcoma	1.54e-05	0.00033	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—SRC—sarcoma	1.53e-05	0.000329	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—SRC—sarcoma	1.53e-05	0.000328	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—KIT—sarcoma	1.52e-05	0.000325	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	1.49e-05	0.00032	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—NRAS—sarcoma	1.48e-05	0.000316	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—NRAS—sarcoma	1.47e-05	0.000315	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	1.46e-05	0.000313	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ENO2—sarcoma	1.46e-05	0.000312	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—HBA1—sarcoma	1.45e-05	0.00031	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CREB1—sarcoma	1.44e-05	0.000309	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—EGFR—sarcoma	1.4e-05	0.0003	CbGpPWpGaD
Temsirolimus—MTOR—Disease—KIT—sarcoma	1.4e-05	0.0003	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	1.38e-05	0.000296	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MDM2—sarcoma	1.37e-05	0.000294	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—MYC—sarcoma	1.37e-05	0.000294	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IGF1R—sarcoma	1.35e-05	0.00029	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—EGFR—sarcoma	1.35e-05	0.000288	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—EGFR—sarcoma	1.34e-05	0.000287	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CREB1—sarcoma	1.33e-05	0.000286	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—KRAS—sarcoma	1.32e-05	0.000284	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—FOXO1—sarcoma	1.29e-05	0.000276	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PDGFRB—sarcoma	1.28e-05	0.000275	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—KRAS—sarcoma	1.27e-05	0.000272	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—KRAS—sarcoma	1.27e-05	0.000271	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PDGFRA—sarcoma	1.26e-05	0.000271	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PLCG1—sarcoma	1.24e-05	0.000265	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—IL2—sarcoma	1.23e-05	0.000263	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	1.23e-05	0.000263	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CCND1—sarcoma	1.2e-05	0.000256	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—MDM2—sarcoma	1.19e-05	0.000256	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—JUN—sarcoma	1.19e-05	0.000256	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CTNNB1—sarcoma	1.18e-05	0.000254	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—HRAS—sarcoma	1.12e-05	0.000241	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MDM2—sarcoma	1.1e-05	0.000236	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ENO2—sarcoma	1.1e-05	0.000236	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—HBA1—sarcoma	1.09e-05	0.000234	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—HRAS—sarcoma	1.08e-05	0.000232	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—HRAS—sarcoma	1.08e-05	0.000231	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—SRC—sarcoma	1.07e-05	0.000229	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—IL2—sarcoma	1.07e-05	0.000229	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KDR—sarcoma	1.06e-05	0.000228	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—VEGFA—sarcoma	1.04e-05	0.000223	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—JUN—sarcoma	1.04e-05	0.000222	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ENO2—sarcoma	1.04e-05	0.000222	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—HBA1—sarcoma	1.03e-05	0.000221	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CTNNB1—sarcoma	1.03e-05	0.000221	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—NRAS—sarcoma	1.03e-05	0.000221	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KIT—sarcoma	9.8e-06	0.00021	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MYC—sarcoma	9.59e-06	0.000206	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CTNNB1—sarcoma	9.51e-06	0.000204	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—EGFR—sarcoma	9.38e-06	0.000201	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PLCG1—sarcoma	9.33e-06	0.0002	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CREB1—sarcoma	9.33e-06	0.0002	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—SRC—sarcoma	9.31e-06	0.0002	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—NRAS—sarcoma	8.95e-06	0.000192	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—KRAS—sarcoma	8.86e-06	0.00019	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PLCG1—sarcoma	8.79e-06	0.000189	CbGpPWpGaD
Temsirolimus—MTOR—Disease—SRC—sarcoma	8.59e-06	0.000184	CbGpPWpGaD
Temsirolimus—MTOR—Disease—NRAS—sarcoma	8.27e-06	0.000177	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—EGFR—sarcoma	8.16e-06	0.000175	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TP53—sarcoma	7.87e-06	0.000169	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MDM2—sarcoma	7.72e-06	0.000165	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—KRAS—sarcoma	7.71e-06	0.000165	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MYC—sarcoma	7.7e-06	0.000165	CbGpPWpGaD
Temsirolimus—MTOR—Disease—EGFR—sarcoma	7.53e-06	0.000161	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—HRAS—sarcoma	7.53e-06	0.000161	CbGpPWpGaD
Temsirolimus—MTOR—Disease—KRAS—sarcoma	7.12e-06	0.000153	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IL2—sarcoma	6.9e-06	0.000148	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ENO2—sarcoma	6.78e-06	0.000145	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—HBA1—sarcoma	6.73e-06	0.000144	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CCND1—sarcoma	6.72e-06	0.000144	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—JUN—sarcoma	6.71e-06	0.000144	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CTNNB1—sarcoma	6.66e-06	0.000143	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—HRAS—sarcoma	6.55e-06	0.00014	CbGpPWpGaD
Temsirolimus—MTOR—Disease—HRAS—sarcoma	6.05e-06	0.00013	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—SRC—sarcoma	6.02e-06	0.000129	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—VEGFA—sarcoma	5.86e-06	0.000126	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NRAS—sarcoma	5.79e-06	0.000124	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PLCG1—sarcoma	5.75e-06	0.000123	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MYC—sarcoma	5.39e-06	0.000116	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—EGFR—sarcoma	5.27e-06	0.000113	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KRAS—sarcoma	4.98e-06	0.000107	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TP53—sarcoma	4.43e-06	9.49e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—HRAS—sarcoma	4.24e-06	9.08e-05	CbGpPWpGaD
